Abstract
Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Current Stem Cell Research & Therapy
Title: Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells
Volume: 4 Issue: 1
Author(s): Noriko Gotoh
Affiliation:
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Abstract: Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Export Options
About this article
Cite this article as:
Gotoh Noriko, Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells, Current Stem Cell Research & Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488809787169048
DOI https://dx.doi.org/10.2174/157488809787169048 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STIP Regulates ERK1/2 Signaling Pathway Involved in Interaction with PP1γ in Lymphoblastic Leukemia
Current Molecular Medicine An Overview of Data Mining Algorithms in Drug Induced Toxicity Prediction
Mini-Reviews in Medicinal Chemistry Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators
Current Organic Chemistry Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation
Current Pharmaceutical Design Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells
Current Cancer Drug Targets CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry A Role for Tumor Suppressor Protein p53 in the Fidelity of DNA Synthesis and Resistance Towards Nucleoside Analogs
Current Cancer Therapy Reviews T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry MicroRNAs and Aging: Biomarkers or Therapeutic Targets?
Current Aging Science The Use of Technetium-99m Radiolabeled Human Antimicrobial Peptides for Infection Specific Imaging
Mini-Reviews in Medicinal Chemistry The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery